$7.16
▼ -0.3% Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics
AtaiBeckley (ATAI) After Eli Lillys Bid Still Looks Fully Valued
AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly
Overview
52-week range
$2.00
$6.75
100% of range
Avg surprise (last 3)
+10.5%
Avg reaction (last 2)
+2.1%
100% positive
Latest IV / EM
24%
EM ±5.6% · $7 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.08 | $-0.11 | +27.3% | +46.7% | +2.7% | earnings |
| Thu Aug 14, 2025 | Jun/2025 | $-0.14 | $-0.12 | -16.7% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.15 | $-0.19 | +21.1% | — | +1.4% | earnings |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$0.10 | -$0.14 | +28.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Revenue | $954,000 | — | $2M |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | $-31M | — | $-20M |
| Net income | $-30M | — | $-26M |
| EPS (diluted) | $-0.08 | — | $-0.15 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Cash & equivalents | $43M | $85M | — |
| Inventory | — | — | — |
| Total current assets | $250M | $276M | — |
| Total assets | $265M | $293M | — |
| Long-term debt | — | — | — |
| Total liabilities | $66M | $71M | — |
| Total equity | $199M | $222M | — |